Lymphoma

A collection of features and news articles published in ASH Clinical News related to lymphoma.

U.K. Says CAR-T Cell Therapy for Non-Hodgkin Lymphoma Is Too Expensive

The U.K.’s National Institute for Health and Care Excellence (NICE) has rejected the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel for use by...
WIB_icon

Insurance Status Contributes to Survival Disparities in Follicular Lymphoma

Patients with follicular lymphoma (FL) who have private health-care insurance live longer than uninsured patients or those who are enrolled in Medicare, according to...

Ibrutinib-Rituximab Combo Granted Priority Review

The FDA granted priority-review designation to the combination of ibrutinib and rituximab for the treatment of Waldenström macroglobulinemia (WM). The Bruton tyrosine kinase inhibitor...

European Commission Approves CAR T-Cell Therapy for Two Blood Cancers

The European Commission (EC) has approved the chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel for the treatment of young patients with B-cell acute lymphocytic...

FDA Approves Treatment for Two Types of NHL

The U.S. Food and Drug Administration (FDA) has approved mogamulizumab-kpkc for intravenous use in patients with relapsed or refractory mycosis fungoides (MF) or Sézary...
WIB_icon

Risk-Adapted, Chemotherapy-Alone Treatment Strategy Effective for Early-Stage Hodgkin Lymphoma

Detection of disease on interim PET/CT scans after two cycles of chemotherapy is a powerful predictor of outcomes in patients with early-stage, non-bulky Hodgkin...

Venetoclax Approved for All Patients With Relapsed/Refractory CLL and SLL

The U.S. Food and Drug Administration (FDA) granted approval to venetoclax for the treatment of patients with previously treated chronic lymphocytic leukemia (CLL) or...

CheckMate 205: Evaluating Nivolumab in Newly Diagnosed Hodgkin Lymphoma

In a study presented by Radhakrishnan Ramchandren, MD, at the 23rd Congress of the European Hematology Association, the four-drug regimen of nivolumab plus doxorubicin,...

Updated Results from JULIET: Tisagenlecleucel Associated With Durable Responses in DLBCL

In May 2018, the U.S. Food and Drug Administration expanded the approval of the chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel to the treatment...

FDA Approves Pembrolizumab for Relapsed/Refractory PMBCL

Pembrolizumab was granted an accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of adult and pediatric patients with refractory...

SHARE